Compare MINISO Group Holding Ltd (MNSO) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MINISO Group Holding Ltd vs Sana Biotechnology Inc — how do they compare? MINISO Group Holding Ltd trades at $11.9 (market cap $3.62B), while Sana Biotechnology Inc trades at $3.77 (market cap $1.13B). The key difference: MINISO Group Holding Ltd is far larger — about 3.2× Sana Biotechnology Inc's market cap, and MINISO Group Holding Ltd pays a 5.53% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| MNSO | SANA | |
|---|---|---|
Market Cap | $3.62B | $1.13B |
Sector | Technology | Health |
52-Week High | $26.63 | $5.92 |
52-Week Low | $11.30 | $2.68 |
Enterprise Value | $4.29B | $1.05B |
Dividend Yield | 5.53% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MNSO trades at $11.895, down 4.99% in the last session amid a neutral technical outlook. Recent earnings show volatility with a Q1 2026 beat but Q3 and Q4 2025 misses, while fundamentals reveal solid revenue growth to $21.44 billion in 2025 and a net income margin of 8.98%. The company announced a $2 billion share repurchase program in June 2026, signaling confidence.
The stock presents a mixed outlook: valuation ratios like P/E of 12.16 appear reasonable, and analyst consensus is 75% buy, but risks include margin pressure from SG&A growth and competitive retail dynamics. Near-term price action hinges on Q2 2026 earnings delivery against expectations of $0.2754 EPS.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
